Dynamic Technology Lab Private Ltd Makes New Investment in LivaNova PLC (NASDAQ:LIVN)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 15,583 shares of the company’s stock, valued at approximately $722,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership acquired a new position in LivaNova during the fourth quarter worth about $21,340,000. Vanguard Group Inc. boosted its position in shares of LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after purchasing an additional 265,291 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of LivaNova in the 4th quarter worth approximately $9,645,000. Wellington Management Group LLP bought a new stake in shares of LivaNova in the 4th quarter worth approximately $8,897,000. Finally, JPMorgan Chase & Co. lifted its stake in LivaNova by 95.7% during the fourth quarter. JPMorgan Chase & Co. now owns 387,772 shares of the company’s stock valued at $17,958,000 after purchasing an additional 189,665 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Mizuho dropped their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $61.17.

LivaNova Price Performance

NASDAQ LIVN opened at $35.95 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 85.60 and a beta of 0.90. The company has a 50 day simple moving average of $43.47 and a 200-day simple moving average of $48.08. LivaNova PLC has a 52-week low of $35.24 and a 52-week high of $64.48.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.